We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 49

Draft guidance regarding self-identification of generic drug facilities and Q&A on generic drug user fee amendments
  • Reed Smith LLP
  • USA
  • September 6 2012

On August 27, 2012, FDA issued draft guidance documents for industry entitled "Self-Identification of Generic Drug Facilities, Sites, and Organizations" and "Generic Drug User Fee Amendments of 2012: Questions and Answers."


FDA final rule implementing device registration and listing requirements
  • Reed Smith LLP
  • USA
  • September 6 2012

The FDA issued a final rule in August amending current regulations to reflect recent statutory amendments to the device registration and listing provisions of the FD&C Act


FDA issues guidance for comment on refuse to accept policy for 510(k)s
  • Reed Smith LLP
  • USA
  • September 5 2012

On August 13, 2012, FDA released draft guidance for public comment entitled “Refuse to Accept Policy for 510(k)s.”


FDA establishes FY 2013 user fee rates for biosimilars and prescription drugs
  • Reed Smith LLP
  • USA
  • September 5 2012

The Food and Drug Administration (FDA) has announced the rates for biosimilar and prescription drug user fees for FY 2013


FDA guidance on FY 2013 medical device user fee small business qualification and certification
  • Reed Smith LLP
  • USA
  • September 5 2012

The FDA has issued guidance on FY 2013 medical device user fees for small businesses


FDA issues draft guidance regarding acceptance & filing review for PMA applications
  • Reed Smith LLP
  • USA
  • July 31 2012

FDA has announced the release of a draft guidance document concerning the necessary elements and contents of a complete premarket approval (PMA) application and the key decisions that are made during the filing process


Medical device user fee rates for FY 2013
  • Reed Smith LLP
  • USA
  • July 31 2012

On July 31, 2012, the FDA published the fee rates and payment procedures for medical device user fees for FY 2013


FDA draft guidances describe product-specific bioequivalence recommendations
  • Reed Smith LLP
  • USA
  • July 16 2012

The FDA has released additional draft and revised draft product-specific bioequivalence (BE) recommendations


FDA proposes unique device identification system for medical devices
  • Reed Smith LLP
  • USA
  • July 16 2012

On July 10, 2012, in response to requirements in legislation that passed Congress with broad bipartisan support, the Food and Drug Administration published a proposed rule that would require most medical devices distributed in the United States to carry a unique device identifier, or UDI, except where the rule provides for alternative placement of the UDI or provides an exception for a particular device or type of device (e.g., devices sold over-the-counter and low risk devices


FDA draft guidance the medical device pre-submission programmeetings with FDA staff
  • Reed Smith LLP
  • USA
  • July 16 2012

On July 13, 2012, FDA issued draft guidance entitled "Medical Devices: The Pre-submission Program and Meetings with FDA Staff."